AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 212 min read$ISRG

Intuitive Surgical (ISRG) Q3 2026 Earnings Call Transcript

Intuitive Surgical (ISRG) reported strong Q3 2026 results, with da Vinci system placements up 28% globally. Da Vinci 5 and SP systems accounted for 65% of placements, and the company announced plans for a new manufacturing facility in Malaysia. ISRG also received several regulatory clearances and expects further reimbursement actions for Ion outside the U.S. The company settled a class action lawsuit related to third-party servicing of da Vinci systems.

Original reporting
finance.yahoo.com
Published Oct 21, 2026, 2:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 2:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Intuitive Surgical (ISRG) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ISRGBullishMed
01

Why it matters

The settlement removes a pending litigation cloud, while product updates signal continued growth but no new financial guidance is provided.

02

Market read

Primary relevance is the legal settlement; operational updates are qualitative and already known.

03

What to watch

Future regulatory scrutiny on third‑party components could still pose risk.

Relevance 7/10Novelty 7/10Timing: today, during the earnings call

Background

The transcript covers Intuitive Surgical's Q3 2026 earnings call, highlighting product placements, regulatory clearances, and a new legal settlement.

Company-level read

Ticker impact

$ISRGBullishHigh confidence
Context

Intuitive Surgical announced a settlement with U.S. customers involved in a class action lawsuit over third‑party remanufacturing of da Vinci instruments and servicing.

Expected impact

likely modest upside as investors price out litigation risk

Evidence & confidence

No financial terms disclosed, but removal of a pending lawsuit is generally viewed favorably.

Market effects

Sector

May reinforce confidence in the surgical robotics sector by showing effective risk management.

Regional

Limited to U.S. customers; no broader regional effect.

Global

Minimal global impact beyond Intuitive Surgical.

Counterpoint

What could challenge this read

The settlement amount could be larger than expected, potentially weighing on cash flow.

Key entities

  • Company
    Intuitive Surgical

    US‑listed maker of da Vinci surgical robots.

Read at source← All news

StoryIntuitive Surgical posts Q3 2026 earnings beat, settles antitrust case and narrows 2026 procedure outlook

Also covered by

4 outlets

Related articles

OCT 21
$ISRGHighAI 8/10

Intuitive Surgical Drops as $450 Million Charge Overshadows Beat

Intuitive Surgical (ISRG) reported Q3 revenue of $3.05B, up 22%, and adjusted earnings of $3.00 per share, beating expectations. However, shares fell due to a $450M antitrust settlement and a cautious growth outlook. GAAP earnings dropped to $1.49 per share, affected by the settlement. The company placed 546 da Vinci systems, with 315 being the newer da Vinci 5 platform.

finance.yahoo.com2 min
OCT 21
$ISRGHighAI 8/10

Intuitive’s shares fall 8% after tempering 2026 procedural growth outlook

Intuitive Surgical reported Q3 revenue of $3.01B, up 22% YoY, but shares fell 8% after lowering its 2026 robotic surgery procedure growth outlook to 14-15% from 13.5-15.5%. The company cited US and Chinese market headwinds. Q3 procedures grew 15% YoY, with 546 da Vinci robots placed. CEO Dave Rosa highlighted strong performance across platforms, including FDA clearance for da Vinci 5 in March 2024.

finance.yahoo.com2 min
OCT 21
$ISRGMedAI 8/10

Stifel reiterates Intuitive Surgical stock rating after Q3 beat

Stifel maintained its Buy rating and $550 target on Intuitive Surgical (ISRG) after Q3 2026 results beat estimates. Revenue grew 20.66% YoY, with procedure growth of 10% in the U.S. and 20% internationally. Analysts have mixed views on the stock, with targets ranging from $400 to $500. Management expects strategic initiatives to boost growth.

investing.com2 min
OCT 21
$ISRGHighAI 8/10

Intuitive Surgical Stock Falls Despite da Vinci 5 Placements Jump

Intuitive Surgical (ISRG) reported Q3 non-GAAP EPS of $3.00, beating estimates, on revenue of $3.05B, also exceeding expectations. GAAP EPS fell due to a $450M litigation charge. Shares dropped 7.76% premarket. Revenue rose 22%, driven by procedure growth and higher lease revenue. Da Vinci system placements increased to 546 from 427 a year earlier, with 315 being the new da Vinci 5 model.

finance.yahoo.com2 min